Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/rosuvastatin/telmisartan - Daewon Pharmaceutical

Drug Profile

Amlodipine/rosuvastatin/telmisartan - Daewon Pharmaceutical

Alternative Names: DW-1501

Latest Information Update: 22 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewon Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dyslipidaemias; Hypertension

Most Recent Events

  • 30 Jun 2018 Discontinued - Phase-III for Dyslipidaemias in South Korea (PO)
  • 30 Jun 2018 Discontinued - Phase-III for Hypertension in South Korea (PO)
  • 01 Sep 2017 Daewon Pharmaceutical completes a phase III trial in Dyslipidaemias and Hypertension in South Korea (PO) (NCT03210532)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top